

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIAALLY-COMPROMISED VASCULAR SMOOTH MUSCLEPage 2
Dkt: 875.039US1In the Claims

Please amend the claims as follows. This set of claims is intended to reflect amendments to claims 1 and 7-10.

o/c to
enter
4/10/03

1. [Currently Amended] A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.

2-5. [Previously Canceled]

6. [Previously Amended] A method of claim 23, wherein the compound administered is 1-p- β -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.

7. [Currently Amended] A method of claim 23, wherein ~~said endothelium damage is the result of~~ the patient has diabetes.

8. [Currently Amended] A method of claim 23, wherein ~~said endothelium damage is the result of~~ patient has had a surgical procedure.

9. [Currently Amended] A method of claim 23, wherein ~~said endothelium damage is the result or cause of~~ the patient has hypertension.

10. [Currently Amended] A method of claim 23, wherein ~~said endothelium damage is the result or cause of~~ the patient has coronary artery disease.

11. [Previously Amended] A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 3

Dkt: 875.039US1


agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

12-13. [Previously Canceled]

14-21. [Previously Withdrawn]

22. [Previously Canceled]

23. [Previously Amended] A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R^4 is H or a lower alkyl radical and R^5 is a lower alkyl radical, or R^4 and R^5 are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R^6 is H or a lower alkyl radical;

R^7 is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R^8 is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. [Previously Canceled]